Drugs / NTX-1472
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07323784 | Dec 2025 → Jan 2027 expected | social phobia | Newleos Therapeutics, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-09-30 | Newleos Therapeutics, Inc. | Regulatory Newleos Therapeutics Announces Clinical Progress Across Neuropsychiatric Pipeline newleos.com ↗
Newleos also announced today that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for a Phase 2 study of NTX-1472, the company’s novel vasopressin 1a (V1a) receptor antagonist for the treatment of social anxiety disorder (SAD). |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-01-06 | Newleos Therapeutics, Inc. | Newleos Therapeutics Announces Dosing of First Participant in SOAR Phase 2 Study of NTX-1472 for Social Anxiety Disorder newleos.com ↗ |
| 2025-09-30 | Newleos Therapeutics, Inc. | Newleos Therapeutics Announces Clinical Progress Across Neuropsychiatric Pipeline newleos.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NTX-1472 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07323784 ↗ |
| Action | Inhibit | “NTX-1472, a V1a Receptor Antagonist” NCT07323784 ↗ |